The development of costs for antidiabetics in statutory and private health insurance in Germany — an analysis of selected influencing factors

Aim The aim of the study underlying this article was to show how the costs of antidiabetics have developed in each case in a collective of insured persons in private and statutory health insurance in a period under investigation that is derived from a comparable data basis for both collectives for the years 2008–2013.